Metallomix

Metallomix is a biotechnology company focused on the discovery and development of therapeutics targeting the metalloproteome. Spun out from the University of Melbourne, the company utilizes a proprietary metalloproteomics platform to identify and characterize metal-binding proteins involved in disease pathways. Their technology enables the systematic mapping of metal-protein interactions, which are essential for the function of approximately one-third of all proteins. Metallomix targets conditions where metal ion homeostasis is disrupted, with a primary focus on oncology and neurodegenerative disorders such as Alzheimer's disease. The company's approach aims to identify novel, druggable targets that are often missed by traditional proteomic methods. By leveraging its expertise in bio-inorganic chemistry, Metallomix is advancing a pipeline of small molecule candidates designed to modulate these metal-dependent biological processes.